gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

C-fos induced growth factor

VEGF-D, Vascular Endothelial Growth Factor D
The protein encoded by this gene is a member of the platelet-derived growth factor/vascular endothelial growth factor (PDGF/VEGF) family and is active in angiogenesis, lymphangiogenesis, and endothelial cell growth. This secreted protein undergoes a complex proteolytic maturation, generating multiple processed forms which bind and activate VEGFR-2 and VEGFR-3 receptors. This protein is structurally and functionally similar to vascular endothelial growth factor C. Read-through transcription has been observed between this locus and the upstream PIR (GeneID 8544) locus. [provided by RefSeq, Feb 2011] (from NCBI)
Top mentioned proteins: vascular endothelial growth factor, VEGF-C, KDR, PCL, CAN
Papers on VEGF-D
Vascular endothelial growth factor-D mediates fibrogenic response in myofibroblasts.
New
Sun et al., Memphis, United States. In Mol Cell Biochem, Feb 2016
Following myocardial infarction (MI), cardiac VEGF-D and VEGF receptor (VEGFR)-3 are significantly upregulated.
IGFBP7 functions as a potential lymphangiogenesis inducer in non-small cell lung carcinoma.
New
Chen et al., Tianjin, China. In Oncol Rep, Jan 2016
The most extensively accepted signaling pathways promoting lymphangiogenesis in tumors include the secreted lymphangiogenic proteins: vascular endothelial growth factor-C (VEGF-C) and VEGF-D, and their cognate receptor on lymphatic endothelium VEGF receptor-3 (VEGFR-3).
Prognostic value of vascular endothelial growth factor-C and podoplanin mRNA expression in esophageal cancer.
New
Nikliński et al., Białystok, Poland. In Oncol Lett, Dec 2015
UNASSIGNED: Vascular endothelial growth factor-C (VEGF-C), VEGF-D, VEGF receptor-3 (VEGFR-3) and podoplanin (PDPN) are involved in the spread of cancer.
Circulating Angiogenic Factors as Biomarkers of Disease Severity and Bacterial Burden in Pulmonary Tuberculosis.
New
Babu et al., Chennai, India. In Plos One, Dec 2015
AIMS/METHODOLOGY: To examine the association of circulating angiogenic factors with PTB, we examined the systemic levels of VEGF-A, VEGF-C, VEGF-D, VEGF-R1, VEGF-R2 and VEGF-R3in individuals with PTB, latent TB (LTB) or no TB infection (NTB).
Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
New
Impact
Van Cutsem et al., Barcelona, Spain. In Lancet Oncol, Aug 2015
We also measured the concentration of 15 proteins of interest-angiopoietin 2, interleukin 6, interleukin 8, placental growth factor, soluble TIE-1, soluble VEGFR1, VEGF-A, VEGF-C, VEGF-D, VEGF-A isoform 121, bone morphogenetic protein 7, macrophage colony-stimulating factor, stromal cell-derived factor-1, tissue inhibitor of metalloproteinase 2, and von Willebrand factor-in plasma samples from 611 patients.
Lymphangioleiomyomatosis: New Treatment Perspectives.
Review
New
Radzikowska, Warsaw, Poland. In Lung, Aug 2015
Comprehension of the disease pathogenesis has resulted in the implementation of other therapeutic agents such as mTOR inhibitors, VEGF-D inhibitors, statins, interferon, chloroquine analogs, cyclin-dependent kinase inhibitors, matrix metalloproteinase inhibitors, aromatase inhibitors, and their combinations.
VEGF Expression in Pancreatic Cancer and Other Malignancies: A Review of the Literature.
Review
New
Săftoiu et al., In Rom J Intern Med, Jul 2015
VEGF protein family currently comprises several members: VEGF (or VEGF-A), VEGF-B, VEGF-C and VEGF-D, VEGF-F, placental growth factor (PlGF), and their receptors VEGFR-1, VEGFR-2 and VEGFR-3.
Rapamycin Protects from Type-I Peritoneal Membrane Failure Inhibiting the Angiogenesis, Lymphangiogenesis, and Endo-MT.
Liappas et al., Madrid, Spain. In Biomed Res Int, 2014
Moreover, the treatment of mesothelial cells with Rapamycin in vitro significantly decreased VEGF synthesis and selectively inhibited the VEGF-C and VEGF-D release when compared with control cells.
Clinical features, epidemiology, and therapy of lymphangioleiomyomatosis.
Review
Moss et al., Bethesda, United States. In Clin Epidemiol, 2014
The severity and progression of disease may be assessed by lung histology scores, quantification of computed tomography, pulmonary function testing, 6-minute walk tests, cardiopulmonary exercise testing, and measurement of serum vascular endothelial growth factor D levels.
The role of angiogenic factors in endometrial cancer.
Review
Stetkiewicz et al., Łódź, Poland. In Prz Menopauzalny, 2014
The VEGF family consists of VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEGF-F and PLGF (placental growth factor).
Management of lymphangioleiomyomatosis.
Review
Moss et al., Bethesda, United States. In F1000prime Rep, 2013
Other targets, for example, estrogen receptors, mitogen-activated protein kinase inhibitors, vascular endothelial growth factor-D signaling pathway, and Src kinase, are also being studied in experimental model systems.
Vascular endothelial growth factor-D is a key molecule that enhances lymphatic metastasis of soft tissue sarcomas.
GeneRIF
Takagishi et al., Maebashi, Japan. In Exp Cell Res, 2012
Vascular endothelial growth factor D was expressed in 4 of 7 primary and 7 of 7 metastatic lesions. In culture, vascular endothelial growth factor D significantly increased the migration of sarcoma cells through lymphatic endothelial monolayers.
The role of the VEGF-C/-D/flt-4 autocrine loop in the pathogenesis of salivary neoplasms.
GeneRIF
Lazaris et al., Athens, Greece. In Pathol Res Pract, 2012
A significant relationship was found in salivary gland tumors with myoepithelial differentiation regarding simultaneous positive staining for VEGF-C/VEGF-D and flt-4
VEGF-D(ilated) lymphatics as gateways to metastasis.
Impact
Rak, Montréal, Canada. In Cancer Cell, 2012
VEGF-C and VEGF-D have been implicated in lymphatic metastasis, mainly as inducers of new intra/peritumoral capillary lymphatics.
VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium.
Impact
Stacker et al., Melbourne, Australia. In Cancer Cell, 2012
Lymphatic metastasis is facilitated by lymphangiogenic growth factors VEGF-C and VEGF-D that are secreted by some primary tumors.
Vascular endothelial growth factor-D promotes growth, lymphangiogenesis and lymphatic metastasis in gallbladder cancer.
GeneRIF
Li et al., Fuzhou, China. In Cancer Lett, 2012
VEGF-D is involved and plays an important role in gallbladder cancer (GBC), progression, suggesting that VEGF-D may be a potential molecular target in the treatment of GBC.
Dilated thin-walled blood and lymphatic vessels in human endometrium: a potential role for VEGF-D in progestin-induced break-through bleeding.
GeneRIF
Rogers et al., Australia. In Plos One, 2011
VEGF-D has a role in progestin-induced break-through bleeding in thin-walled blood and lymphatic endometrial vessels
Co-expression of α9β1 integrin and VEGF-D confers lymphatic metastatic ability to a human breast cancer cell line MDA-MB-468LN.
GeneRIF
Lala et al., London, Canada. In Plos One, 2011
Differential capacity for VEGF-D production and integrin alpha 9 beta 1 expression by human breast cancer cell line MDA-MB-468LN jointly contributed to their lymphatic metastatic phenotype.
Efficacy and safety of sirolimus in lymphangioleiomyomatosis.
Impact
MILES Trial Group et al., Cincinnati, United States. In N Engl J Med, 2011
As compared with the placebo group, the sirolimus group had improvement from baseline to 12 months in measures of forced vital capacity, functional residual capacity, serum vascular endothelial growth factor D (VEGF-D), and quality of life and functional performance.
Therapeutic differentiation and maturation of lymphatic vessels after lymph node dissection and transplantation.
Impact
Alitalo et al., Helsinki, Finland. In Nat Med, 2007
Treatment of lymph node-excised mice with adenovirally delivered vascular endothelial growth factor-C (VEGF-C) or VEGF-D induced robust growth of the lymphatic capillaries, which gradually underwent intrinsic remodeling, differentiation and maturation into functional collecting lymphatic vessels, including the formation of uniform endothelial cell-cell junctions and intraluminal valves.
share on facebooktweetadd +1mail to friends